International Clinical Trial: Multi-center, Open-label, Single-arm Phase II Clinical trial of Sacituzumab-Govitecan plus Q901 in Advanced TNBC

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (KCT0012337) titled 'Multi-center, Open-label, Single-arm Phase II Clinical trial of Sacituzumab-Govitecan plus Q901 in Advanced TNBC' on July 27.

Study Type: Interventional Study

Study Design: Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable

Primary Sponsor: Yonsei University Health System, Severance Hospital

Condition:

Neoplasms

Intervention: Drug : This is a single-arm study in which all subjects receive the combination of sacituzumab govitecan (SG) and Q901. SG 10 mg/kg is administered as an intravenous infusion on Days 1 and 8 of each 21-day cycle the first inf...